Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine


Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine

PR Newswire

VIENNA, July 29, 2014 /PRNewswire/ --

 

What:   AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community.

When:   Thursday, July 31, 2014

        11.00 am EST (Eastern Standard Time)

        03.00 pm UTC (Coordinated Universal Time)

Where:  New York Marriott East Side Hotel

        525 Lexington Ave, New York

        Room Morgan A

Live webcast link: http://totalwebcasting.com/view/?id=affiris

Who:    Walter Schmidt, PhD: CEO & Co-founder, AFFiRiS AG

        Todd Sherer, PhD: CEO, The Michael J. Fox Foundation

        Prof. Achim Schneeberger, MD: CMO, AFFiRiS AG

If you are unable to attend the press conference, please visit the aforementioned web link for a live webcast. An embedded message board will allow you to participate in the Q&A. A recording of the conference will be made available immediately after the press conference at http://totalwebcasting.com/view/?id=affiris

About AFFiRiS AG 

Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria (http://www.affiris.com).

About The Michael J. Fox Foundation for Parkinson's Research 

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers.  In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

Contact:
Till Jelitto or Martina Herrmann-Thurner
PR&D - Public Relations for Research & Education
+43-1-505-70-44
jelitto@prd.at or herrmannthurner@prd

SOURCE AFFiRiS AG

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here